scispace - formally typeset
Search or ask a question
Institution

University of Texas Health Science Center at Houston

EducationHouston, Texas, United States
About: University of Texas Health Science Center at Houston is a education organization based out in Houston, Texas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27309 authors who have published 42520 publications receiving 2151596 citations. The organization is also known as: UTHealth & The UT Health Science Center at Houston.


Papers
More filters
Journal ArticleDOI
TL;DR: The data suggest that GNPs are able to cross the blood-brain barrier and accumulate in the neural tissue, and the accumulation of the particles does not produce sub-acute physiological damage.

523 citations

Journal ArticleDOI
TL;DR: These AMIA recommendations are intended to stimulate informed debate, provide a plan to increase understanding of the impact of usability on the effective use of health IT, and lead to safer and higher quality care with the adoption of useful and usable EHR systems.

523 citations

Journal ArticleDOI
TL;DR: The CheckMate 032 trial as mentioned in this paper evaluated the activity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after previous platinum-based chemotherapy.
Abstract: Summary Background Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy. We assessed the activity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after previous platinum-based chemotherapy. Methods In this phase 1/2, multicentre, open-label study, we enrolled patients (age ≥18 years) with urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra at 16 sites in Finland, Germany, Spain, the UK, and the USA. Patients were not selected by PD-L1 expression, but tumour PD-L1 membrane expression was assessed retrospectively. Patients received nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation because of unacceptable toxicity or other protocol-defined reasons, whichever occurred later. The primary endpoint was objective response by investigator assessment. All patients who received at least one dose of the study drug were included in the analyses. We report an interim analysis of this ongoing trial. CheckMate 032 is registered with ClinicalTrials.gov, NCT01928394. Findings Between June 5, 2014, and April 24, 2015, 86 patients with metastatic urothelial carcinoma were enrolled in the nivolumab monotherapy group and 78 received at least one dose of treatment. At data cutoff (March 24, 2016), the minimum follow-up was 9 months (median 15·2 months, IQR 12·9–16·8). A confirmed investigator-assessed objective response was achieved in 19 (24·4%, 95% CI 15·3–35·4) of 78 patients. Grade 3–4 treatment-related adverse events occurred in 17 (22%) of 78 patients; the most common were elevated lipase (four [5%]), elevated amylase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neutrophil count (two [3%] each). Serious adverse events were reported in 36 (46%) of 78 patients and eight (10%) had a serious adverse event judged to be treatment related. Two (3%) of 78 patients discontinued because of treatment-related adverse events (grade 4 pneumonitis and grade 4 thrombocytopenia) and subsequently died. Interpretation Nivolumab monotherapy was associated with a substantial and durable clinical response and a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma. These data support further investigation of nivolumab monotherapy in advanced urothelial carcinoma. Funding Bristol-Myers Squibb.

523 citations

Journal ArticleDOI
Patrick T. Ellinor, Kathryn L. Lunetta1, Christine M. Albert2, Christine M. Albert3, Nicole L. Glazer4, Marylyn D. Ritchie5, Albert V. Smith6, Dan E. Arking7, Martina Müller-Nurasyid8, Bouwe P. Krijthe9, Steven A. Lubitz3, Steven A. Lubitz2, Joshua C. Bis4, Mina K. Chung10, Mina K. Chung11, Marcus Dörr, Kouichi Ozaki, Jason D. Roberts12, J. Gustav Smith13, J. Gustav Smith14, Arne Pfeufer15, Moritz F. Sinner1, Moritz F. Sinner2, Moritz F. Sinner8, Kurt Lohman16, Jingzhong Ding16, Nicholas L. Smith, Jonathan D. Smith11, Jonathan D. Smith10, Michiel Rienstra, Kenneth Rice4, David R. Van Wagoner10, David R. Van Wagoner11, Jared W. Magnani1, Reza Wakili8, Sebastian Clauss8, Jerome I. Rotter17, Gerhard Steinbeck8, Lenore J. Launer18, Robert W. Davies12, Matthew Borkovich12, Tamara B. Harris18, Honghuang Lin1, Uwe Völker, Henry Völzke, David J. Milan2, Albert Hofman9, Eric Boerwinkle19, Lin Y. Chen20, Elsayed Z. Soliman16, Benjamin F. Voight14, Guo Li4, Aravinda Chakravarti7, Michiaki Kubo, Usha B. Tedrow2, Usha B. Tedrow3, Lynda M. Rose3, Paul M. Ridker2, Paul M. Ridker3, David Conen21, Tatsuhiko Tsunoda, Tetsushi Furukawa22, Nona Sotoodehnia4, Siyan Xu1, Naoyuki Kamatani, Daniel Levy1, Yusuke Nakamura23, Babar Parvez24, Saagar Mahida2, Karen L. Furie2, Jonathan Rosand2, Raafia Muhammad24, Bruce M. Psaty, Thomas Meitinger15, Siegfried Perz, H-Erich Wichmann8, Jacqueline C.M. Witteman9, W. H. Linda Kao25, Sekar Kathiresan2, Sekar Kathiresan14, Dan M. Roden24, André G. Uitterlinden9, Fernando Rivadeneira9, Barbara McKnight4, Marketa Sjögren13, Anne B. Newman26, Yongmei Liu16, Michael H. Gollob12, Olle Melander13, Toshihiro Tanaka, Bruno H. Stricker, Stephan B. Felix, Alvaro Alonso20, Dawood Darbar24, John Barnard10, Daniel I. Chasman2, Daniel I. Chasman3, Susan R. Heckbert27, Susan R. Heckbert4, Emelia J. Benjamin, Vilmundur Gudnason6, Stefan Kääb8 
TL;DR: Six new atrial fibrillation susceptibility loci implicate candidate genes that encode transcription factors related to cardiopulmonary development, cardiac-expressed ion channels and cell signaling molecules that are associated with stroke, heart failure and death.
Abstract: Atrial fibrillation is a highly prevalent arrhythmia and a major risk factor for stroke, heart failure and death. We conducted a genome-wide association study (GWAS) in individuals of European ancestry, including 6,707 with and 52,426 without atrial fibrillation. Six new atrial fibrillation susceptibility loci were identified and replicated in an additional sample of individuals of European ancestry, including 5,381 subjects with and 10,030 subjects without atrial fibrillation (P < 5 × 10(-8)). Four of the loci identified in Europeans were further replicated in silico in a GWAS of Japanese individuals, including 843 individuals with and 3,350 individuals without atrial fibrillation. The identified loci implicate candidate genes that encode transcription factors related to cardiopulmonary development, cardiac-expressed ion channels and cell signaling molecules.

523 citations


Authors

Showing all 27450 results

NameH-indexPapersCitations
Paul M. Ridker2331242245097
Eugene Braunwald2301711264576
Eric N. Olson206814144586
Hagop M. Kantarjian2043708210208
André G. Uitterlinden1991229156747
Gordon B. Mills1871273186451
Eric Boerwinkle1831321170971
Bruce M. Psaty1811205138244
Aaron R. Folsom1811118134044
Daniel R. Weinberger177879128450
Bharat B. Aggarwal175706116213
Richard A. Gibbs172889249708
Russel J. Reiter1691646121010
James F. Sallis169825144836
Steven N. Blair165879132929
Network Information
Related Institutions (5)
University of California, San Francisco
186.2K papers, 12M citations

98% related

Baylor College of Medicine
94.8K papers, 5M citations

98% related

Emory University
122.4K papers, 6M citations

98% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

97% related

University of Pittsburgh
201K papers, 9.6M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202342
2022231
20213,048
20202,807
20192,467
20182,224